propentofylline ihhibits reuptake of the neuromodulator modulator adenosine, resulting in extracellular accumulation of this molecule and potentiation of the neuroproprotective effect which it exerts via adenosine sine A1 and a2 receptor (inhibition of excitatoryamino acid release, vasodilatory and antithrombotic effect leading to increased cerebral blood flow and inhibition of neutrophil actvation. paradoxically, propentofylline also directly an
agonises adenosine receptor, but the clinical relevance of this activity remains unclear. popentofylline also inhibits cyclic adenosine monophosphate (cAMP) phosphodiesterase and cyclic guanosine monophosphate (cCMP) phosphodiesterase, resulting in increased levals of cAMP and cGMP, which are important second messengers involved in regulation of neural function. cantly the release of interleukin-1B and interleukin-6 from activation human blood mono nuclear cell and the release of tomur necrosis factor and from activation microglial and peripheral blood mononuclear cell.